Literature DB >> 10773877

p27Kip1-deficient mice exhibit accelerated growth hormone-releasing hormone (GHRH)-induced somatotrope proliferation and adenoma formation.

L T Teixeira1, H Kiyokawa, X D Peng, K T Christov, L A Frohman, R D Kineman.   

Abstract

p27Kip1 (p27) controls cell cycle progression by binding to and inhibiting the activity of cyclin dependent kinases. Disruption of the p27 gene in mice (p27-/-) results in increased body growth with a disproportionate enlargement of the spleen, thymus, testis, ovary and pituitary. The increase in pituitary size is due to selective hyperplasia of the intermediate lobe (IL) while the anterior lobe (AL) is not overtly affected. p27 heterozygous mice (p27+/-), as well as p27-/- mice, are hypersensitive to radiation- and chemical-induced tumors compared to wildtype (p27+/+) littermates. Therefore, unlike classical tumor suppressors, only a reduction in p27 levels is necessary to predispose tissues to secondary tumor promoters. Consistent with these studies is the fact that the p27 gene sequence and mRNA levels appear normal in human pituitary adenomas while p27 protein levels are decreased. Therefore, a reduction in p27 levels could be sufficient to sensitize pituitary cells to tumorigenic factors. To test this hypothesis, metallothionein promoter-driven, human growth hormone-releasing hormone (MT-hGHRH) transgenic mice, that exhibit somatotrope hyperplasia before 9 months of age and subsequent adenoma formation with 30 - 40% penetrance, were crossbred with p27+/- mice for two successive generations to produce p27+/+, p27+/- and p27-/- mice that expressed the hGHRH transgene. At 10 - 12 weeks of age, p27-/- and p27+/+, hGHRH mice were larger than their p27+/+ littermates and displayed characteristic hyperplasia of the IL and AL, respectively. Expression of the hGHRH transgene in both p27+/- and p27-/- mice selectively expanded the population of somatotropes within the AL, where pituitaries of p27+/-, hGHRH and p27-/-, hGHRH mice were two- and fivefold larger than p27+/+, hGHRH pituitaries, respectively. There was also a synergistic effect of hGHRH transgene expression and p27-deficiency on liver, spleen and ovarian growth. At 6 - 8 months of age, 83% of p27+/-, hGHRH mice displayed macroscopic AL adenomas (>100 mg), while all pituitaries from p27+/+, hGHRH mice remained hyperplastic (<20 mg). In contrast to the dramatic effects of p27-deficiency on hGHRH-induced organ growth, elimination of p53, by crossbreeding MT-hGHRH mice to p53-deficient mice, did not augment the hyperplastic/tumorigenic effects of hGHRH transgene expression. Taken together these results demonstrate that a reduction in p27 expression is sufficient to sensitize somatotropes to the proliferative actions of excess GHRH, resulting in the earlier appearance and increased penetrance of hGHRH-induced pituitary tumors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10773877     DOI: 10.1038/sj.onc.1203490

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

Review 1.  PRKAR1A and the evolution of pituitary tumors.

Authors:  Lawrence S Kirschner
Journal:  Mol Cell Endocrinol       Date:  2010-05-06       Impact factor: 4.102

2.  Morphologic and molecular analysis of estrogen-induced pituitary tumorigenesis in targeted disruption of transforming growth factor-beta receptor type II and/or p27 mice.

Authors:  H Ikeda; T Yoshimoto; N Shida; I Miyoshi; K Nakayama; K Nakayama; M Oshima; M M Taketo
Journal:  Endocrine       Date:  2001-10       Impact factor: 3.633

3.  Pituitary hyperplasia in glycoprotein hormone alpha subunit-, p18(INK4C)-, and p27(kip-1)-null mice: analysis of proteins influencing p27(kip-1) ubiquitin degradation.

Authors:  Ricardo V Lloyd; Katharina H Ruebel; Shuya Zhang; Long Jin
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

4.  Genetic mosaics reveal both cell-autonomous and cell-nonautonomous function of murine p27Kip1.

Authors:  Wei-Ming Chien; Stuart Rabin; Everardo Macias; Paula L Miliani de Marval; Kendra Garrison; Jason Orthel; Marcelo Rodriguez-Puebla; Matthew L Fero
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-03       Impact factor: 11.205

5.  Use of the metallothionein promoter-human growth hormone-releasing hormone (GHRH) mouse to identify regulatory pathways that suppress pituitary somatotrope hyperplasia and adenoma formation due to GHRH-receptor hyperactivation.

Authors:  Raul M Luque; Beatriz S Soares; Xiao-ding Peng; Sonia Krishnan; Jose Cordoba-Chacon; Lawrence A Frohman; Rhonda D Kineman
Journal:  Endocrinology       Date:  2009-04-02       Impact factor: 4.736

6.  Pituitary-specific knockout of the Carney complex gene Prkar1a leads to pituitary tumorigenesis.

Authors:  Zhirong Yin; Lisa Williams-Simons; A F Parlow; Sylvia Asa; Lawrence S Kirschner
Journal:  Mol Endocrinol       Date:  2007-11-01

7.  An essential role of p27 downregulation in fenvalerate-induced cell growth in human uterine leiomyoma and smooth muscle cells.

Authors:  Xiaohua Gao; Linda Yu; Lysandra Castro; Charles J Tucker; Alicia B Moore; Hang Xiao; Darlene Dixon
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-07-31       Impact factor: 4.310

8.  p27(Kip1) deficiency promotes prostate carcinogenesis but does not affect the efficacy of retinoids in suppressing the neoplastic process.

Authors:  Winna Taylor; Amanda Mathias; Arshia Ali; Hengning Ke; Nikolay Stoynev; Anne Shilkaitis; Albert Green; Hiroaki Kiyokawa; Konstantin Christov
Journal:  BMC Cancer       Date:  2010-10-08       Impact factor: 4.430

9.  The novel protective role of P27 in MLN4924-treated gastric cancer cells.

Authors:  Q Zhang; D Hou; Z Luo; P Chen; B Lv; L Wu; Y Ma; Y Chu; H Liu; F Liu; S Yu; J Zhang; D Yang; J Liu
Journal:  Cell Death Dis       Date:  2015-08-27       Impact factor: 8.469

10.  MEN4, the MEN1 Mimicker: A Case Series of three Phenotypically Heterogenous Patients With Unique CDKN1B Mutations.

Authors:  Amanda Seabrook; Ayanthi Wijewardene; Sunita De Sousa; Tang Wong; Nisa Sheriff; Anthony J Gill; Rakesh Iyer; Michael Field; Catherine Luxford; Roderick Clifton-Bligh; Ann McCormack; Katherine Tucker
Journal:  J Clin Endocrinol Metab       Date:  2022-07-14       Impact factor: 6.134

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.